NASDAQ:MLYS Mineralys Therapeutics (MLYS) Stock Price, News & Analysis $11.23 -0.71 (-5.95%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.10▼$11.9350-Day Range$9.13▼$14.5852-Week Range$5.85▼$16.91Volume101,807 shsAverage Volume183,010 shsMarket Capitalization$557.56 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mineralys Therapeutics alerts: Email Address Mineralys Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside167.1% Upside$30.00 Price TargetShort InterestBearish6.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingSelling Shares$9.20 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.08) to ($3.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector641st out of 910 stocksPharmaceutical Preparations Industry293rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMineralys Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMineralys Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Mineralys Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.46% of the float of Mineralys Therapeutics has been sold short.Short Interest Ratio / Days to CoverMineralys Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Mineralys Therapeutics has recently decreased by 3.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMineralys Therapeutics does not currently pay a dividend.Dividend GrowthMineralys Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLYS. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Mineralys Therapeutics this week, compared to 2 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mineralys Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,204,818.00 in company stock.Percentage Held by Insiders33.24% of the stock of Mineralys Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.46% of the stock of Mineralys Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mineralys Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Mineralys Therapeutics are expected to decrease in the coming year, from ($3.08) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mineralys Therapeutics is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mineralys Therapeutics is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMineralys Therapeutics has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mineralys Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis new buy indicator has the internet shook. In the last few weeks we’ve seen countless people talking about a totally new stock indicator called Platform X… It identifies the markets strongest stocks, then delivers customized buy signals for those stocks… Even as the market stalled out it nailed several calls including a 100%+ winner on Newmont mining… At first we thought this was some sort of hocus pocus indicator… But it turned out to be a very viable tool for trading today’s market action… Which is the reason for today's email…To check it out, just follow this link here. About Mineralys Therapeutics Stock (NASDAQ:MLYS)Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Read More MLYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLYS Stock News HeadlinesSeptember 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYSAugust 29, 2024 | msn.comMineralys Therapeutics to Speak at Wells Fargo Healthcare ConferenceSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | finance.yahoo.comMineralys Therapeutics to Participate in the Wells Fargo Healthcare ConferenceAugust 26, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc. - MLYSAugust 16, 2024 | uk.investing.comMineralys stock keeps Buy rating, PT at Goldman Sachs post Q2August 16, 2024 | investing.comMineralys Therapeutics kicks off key program, shares hold buy rating with StifelAugust 15, 2024 | markets.businessinsider.comBuy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat TrialsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 15, 2024 | msn.comMineralys Therapeutics Posts Q2 Financial Results, Updates on Clinical TrialsAugust 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)August 14, 2024 | finanznachrichten.deMineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comMineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | seekingalpha.comMineralys Therapeutics, Inc. (MLYS) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | markets.businessinsider.comMLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024August 13, 2024 | seekingalpha.comMineralys Therapeutics, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 7, 2024 | msn.comMineralys Therapeutics to Announce Q2 2024 Financial ResultsJune 14, 2024 | globenewswire.comMineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D.See More Headlines Receive MLYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MLYS CUSIPN/A CIK1933414 Webwww.mineralystx.com Phone888-378-6240FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+167.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,900,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.61% Return on Assets-40.06% Debt Debt-to-Equity RatioN/A Current Ratio11.20 Quick Ratio11.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book1.93Miscellaneous Outstanding Shares49,649,000Free Float33,146,000Market Cap$557.56 million OptionableOptionable Beta1.93 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Comp: $69.33kMr. Jon Congleton (Age 61)CEO & Director Comp: $775.77kMr. Adam Scott Levy (Age 46)CFO & Secretary Comp: $655.58kDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Comp: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical OperationsMore ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXCatalyst PharmaceuticalsNASDAQ:CPRXAmphastar PharmaceuticalsNASDAQ:AMPHVerona PharmaNASDAQ:VRNAMaravai LifeSciencesNASDAQ:MRVIView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 200,000 shares on 8/20/2024Ownership: 1.073%Driehaus Capital Management LLCBought 74,074 shares on 8/16/2024Ownership: 0.518%Blue Owl Capital Holdings LPSold 90,741 shares on 8/15/2024Ownership: 0.907%Lion Point Capital LPBought 19,000 shares on 8/15/2024Ownership: 0.159%The Manufacturers Life Insurance Company Bought 12,432 shares on 8/15/2024Ownership: 0.025%View All Insider TransactionsView All Institutional Transactions MLYS Stock Analysis - Frequently Asked Questions How have MLYS shares performed this year? Mineralys Therapeutics' stock was trading at $8.60 at the beginning of the year. Since then, MLYS shares have increased by 30.6% and is now trading at $11.23. View the best growth stocks for 2024 here. How were Mineralys Therapeutics' earnings last quarter? Mineralys Therapeutics, Inc. (NASDAQ:MLYS) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.10. When did Mineralys Therapeutics IPO? Mineralys Therapeutics (MLYS) raised $180 million in an initial public offering on Friday, February 10th 2023. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Mineralys Therapeutics' major shareholders? Top institutional investors of Mineralys Therapeutics include Adams Street Partners LLC (3.40%), American Century Companies Inc. (1.50%), Nantahala Capital Management LLC (1.07%) and Blue Owl Capital Holdings LP (0.91%). Insiders that own company stock include Brian Taylor Slingsby, Samsara Biocapital Gp, Llc, Hbm Healthcare Investments (Ca, Ra Capital Management, LP, Jon Congleton, Adam Scott Levy and David Malcom Rodman. View institutional ownership trends. How do I buy shares of Mineralys Therapeutics? Shares of MLYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLYS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.